How are Brainsway (BWAY) Ordinary Shares related to its American Depositary Shares?

The filing notes that Brainsway’s Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one Ordinary Share, linking U.S.-traded ADSs to the underlying Israeli-listed equity.

Brainsway (BWAY) chief scientist trims stake with 7,000-share sale

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Brainsway Ltd. Chief Scientist Dr. Roth Yiftach reported open-market sales of a total of 7,000 Ordinary Shares on June 1–2, 2026. The filing notes sale prices between NIS 42.0035 and NIS 43.64 per share. After these transactions, he directly holds 1,072,305 Ordinary Shares, including shares held jointly with his spouse and 5,000 unvested RSUs that vest in stages through March 10, 2030. The Ordinary Shares may also be represented by American Depositary Shares, each currently equal to one Ordinary Share.

Insider Trade Summary

4 transactions reported

Net Sell 4 txns

Insider Roth Yiftach

Role Chief Scientist

Sold 7,000 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,000	$0.00	--
Sale	Ordinary Shares	2,000	$0.00	--
Sale	Ordinary Shares	2,000	$0.00	--
Sale	Ordinary Shares	2,000	$0.00	--

Holdings After Transaction: Ordinary Shares — 1,074,305 shares (Direct, null)

Footnotes (1)

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The sale price was NIS 43.64 per share. This figure includes ordinary shares held jointly by Dr. Roth and his spouse and (i) 15,000 ordinary shares and (ii) unvested restricted stock units ("RSUs") to receive 5,000 ordinary shares, with 1,250 vesting on March 10, 2027 and the remainder vesting in equal quarterly installments until March 10, 2030, each RSU representing a contingent right to receive one ordinary share. The sale price was NIS 43.45 per share. The sale price was NIS 43 per share. The sale price was NIS 42.0035 per share.

Key Figures

Shares sold: 7,000 Ordinary Shares Holding after transactions: 1,072,305 Ordinary Shares Sale price range: NIS 42.0035–NIS 43.64 per share +2 more

5 metrics

Shares sold 7,000 Ordinary Shares Open-market sales on June 1–2, 2026

Holding after transactions 1,072,305 Ordinary Shares Direct ownership following reported sales

Sale price range NIS 42.0035–NIS 43.64 per share Prices disclosed in transaction footnotes

Unvested RSUs 5,000 RSUs Each RSU for one Ordinary Share, vesting through March 10, 2030

Additional ordinary shares 15,000 ordinary shares Included in the reported ownership figure per footnote

Key Terms

American Depositary Shares, restricted stock units ("RSUs"), open-market sale, contingent right to receive one ordinary share

4 terms

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted stock units ("RSUs") financial

"unvested restricted stock units ("RSUs") to receive 5,000 ordinary shares, with 1,250 vesting on March 10, 2027"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 04:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roth Yiftach

(Last)

(First)

(Middle)

16 HARTUM STREET, RAD TOWER, 14TH FLOOR

HAR HAHOTZVIM

(Street)

JERUSALEM

9777516

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Brainsway Ltd. [ BWAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientist

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	06/01/2026		S		2,000	D	⁽²⁾	1,077,305⁽³⁾	D
Ordinary Shares⁽¹⁾	06/01/2026		S		2,000	D	⁽⁴⁾	1,075,305⁽³⁾	D
Ordinary Shares⁽¹⁾	06/02/2026		S		1,000	D	⁽⁵⁾	1,074,305⁽³⁾	D
Ordinary Shares⁽¹⁾	06/02/2026		S		2,000	D	⁽⁶⁾	1,072,305⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The sale price was NIS 43.64 per share.

3. This figure includes ordinary shares held jointly by Dr. Roth and his spouse and (i) 15,000 ordinary shares and (ii) unvested restricted stock units ("RSUs") to receive 5,000 ordinary shares, with 1,250 vesting on March 10, 2027 and the remainder vesting in equal quarterly installments until March 10, 2030, each RSU representing a contingent right to receive one ordinary share.

4. The sale price was NIS 43.45 per share.

5. The sale price was NIS 43 per share.

6. The sale price was NIS 42.0035 per share.

	/s/ Yiftach Roth	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Brainsway (BWAY) report for Dr. Roth Yiftach?

Brainsway reported that Chief Scientist Dr. Roth Yiftach sold 7,000 Ordinary Shares in open-market transactions on June 1–2, 2026. These sales are disclosed in a Form 4 insider filing and detail changes in his direct share ownership.

How many Brainsway (BWAY) shares does Dr. Roth Yiftach hold after the Form 4 sales?

After the reported sales, Dr. Roth Yiftach directly holds 1,072,305 Ordinary Shares of Brainsway. This figure includes shares held jointly with his spouse and certain additional ordinary shares referenced in the filing footnotes.

At what prices did Dr. Roth Yiftach sell Brainsway (BWAY) shares?

The Form 4 footnotes state that Dr. Roth Yiftach’s share sales occurred at prices between NIS 42.0035 and NIS 43.64 per Ordinary Share. Each transaction reflects an open-market sale within this disclosed price range.

How many Brainsway (BWAY) shares did Dr. Roth Yiftach sell in this Form 4?

The Form 4 shows that Dr. Roth Yiftach sold a total of 7,000 Ordinary Shares across four open-market transactions. Two trades were for 2,000 shares each and two additional trades accounted for the remaining 3,000 shares.

Does Dr. Roth Yiftach hold any unvested RSUs in Brainsway (BWAY)?

Yes. The footnotes state he has 5,000 unvested restricted stock units, each representing a right to one Ordinary Share. 1,250 RSUs vest on March 10, 2027, with the remainder vesting in equal quarterly installments until March 10, 2030.